Foster Dykema Cabot & Partners’s DexCom DXCM Stock Holding History

Foster Dykema Cabot & Partners’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-8	Closed	-$538	–	358
2025 Q3	$538	Buy	+8	New	+$633	﹤0.01%	410

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Foster Dykema Cabot & Partners's DXCM Position: Q4 2025 in Review

Foster Dykema Cabot & Partners sold out of DexCom (DXCM) in Q4 2025, closing a stake of 8 shares — an estimated $538 sold.

Foster Dykema Cabot & Partners first reported a position in DXCM in Q3 2025 and held it in 1 quarter. The position peaked at $538 in Q3 2025. 922 funds tracked by Wall St. Rank hold DXCM as of Q4 2025.

Foster Dykema Cabot & Partners reported no remaining DexCom position as of Q4 2025 after selling out during the quarter.
Foster Dykema Cabot & Partners sold 8 DexCom shares in Q4 2025, an estimated $538.
Foster Dykema Cabot & Partners first reported a position in DexCom in Q3 2025 and held it in 1 quarter.
Foster Dykema Cabot & Partners's DexCom position peaked at $538 in Q3 2025.
922 funds tracked by Wall St. Rank held DexCom as of Q4 2025.

Based on Foster Dykema Cabot & Partners's 13F filing for Q4 2025, filed 12 Feb 2026.